

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

BC

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A01N 37/18, A61K 49/00, C12N 5/00, 5/02	A1	(11) International Publication Number: WO 00/19823 (43) International Publication Date: 13 April 2000 (13.04.00)
(21) International Application Number: PCT/US99/23393 (22) International Filing Date: 7 October 1999 (07.10.99) (30) Priority Data: 60/103,385 7 October 1998 (07.10.98) US 60/116,409 19 January 1999 (19.01.99) US (71) Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS [US/US]; 2404 North University Avenue, Little Rock, AR 72207-3608 (US). (72) Inventors: MANOLAGAS, Stavros, C.; 35 River Ridge Circle, Little Rock, AR 72227 (US). JILKA, Robert, L.; 14202 Clarborne, Little Rock, AR 72211 (US). WEINSTEIN, Robert, S.; 11 Chalmette, Little Rock, AR 72211 (US). BELLIDO, Teresita; 9 Westglen Cove, Little Rock, AR 72211 (US). (74) Agent: ADLER, Benjamin, A.; McGregor & Adler, 8011 Candle Lane, Houston, TX 77071 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: METHODS OF SCREENING FOR APOPTOSIS-CONTROLLING AGENTS FOR BONE ANABOLIC THERAPIES AND USES THEREOF (57) Abstract The present invention demonstrates that human parathyroid hormone 1-34 [hPTH(1-34)] exerts anti-apoptotic effects on osteoblasts when administered in an intermittent fashion to mice <i>in vivo</i> . The present invention further demonstrates that bovine PTH(1-34) [bPTH(1-34)] prevents glucocorticoid-induced apoptosis of osteoblastic and osteocytic cells <i>in vitro</i> . Therefore, the present invention demonstrates that the previously established anabolic effects of PTH on the skeleton are mediated by its ability to postpone osteoblast apoptosis, as opposed to a stimulatory effect on osteoblastogenesis. The present invention provides methods of screening agents for anti-apoptotic effects on osteoblasts, wherein such agents stimulate and/or restore bone in osteopenic individuals, or prevent bone loss caused by agents such as glucocorticoids.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

METHODS OF SCREENING FOR APOPTOSIS-CONTROLLING AGENTS FOR BONE ANABOLIC THERAPIES AND USES THEREOF

5

BACKGROUND OF THE INVENTION

Cross-Reference to Related Applications

10 This application claims the benefit of priority of U.S. provisional application 60/116,409, January 19, 1999 and 60/103,385 filed October 7, 1998, now abandoned.

Federal Funding Legend

15 This invention was produced in part using funds obtained through grant PO1-AG13918 from the National Institutes of Health. Consequently, the federal government has certain rights in this invention.

20 ~~Field of the Invention~~

 The present invention relates generally to bone physiology. More specifically, the present invention relates to inhibiting apoptosis of osteoblasts and osteocytes.

Description of the Related Art

Remodeling of the human adult skeleton is carried out by teams of juxtaposed osteoclasts and osteoblasts. Osteoclasts and osteoblasts are specialized cell types that originate from hematopoietic and mesenchymal progenitors of the bone marrow, respectively. During bone remodeling, old bone is resorbed by osteoclasts and replaced with new bone by osteoblasts. After they have completed bone matrix synthesis, osteoblasts become osteocytes or lining cells, or they undergo apoptosis.

10 The osteoblasts and osteoclasts that carry out bone remodeling comprise the basic multi-cellular unit (BMU). Because the lifetime of the basic multi-cellular unit is longer than the lifetime of the individual osteoclasts and osteoblasts, new cells must be continuously supplied from progenitors in the bone marrow for progression to occur.

15 Continuous and orderly supply of these cells, as well as the appropriate rate of apoptosis, is essential for bone homeostasis, as increased or decreased production of osteoclasts or osteoblasts leads to osteoporosis, Paget's, metastatic and renal bone disease. Little is known, however, about the factors that regulate osteogenesis in postnatal life and how

20 osteoblastogenesis and osteoclastogenesis are coordinated to ensure a balance between formation and resorption during remodeling.

During the last few years, it has been established that the process of bone remodeling is regulated locally by growth factors and cytokines produced in the bone micro-environment. In addition,

25 systemic hormones modulate the production and/or action of locally produced cytokines and growth factors, thereby influencing the rate of bone remodeling. Bone morphogenetic proteins (BMPs) are unique among growth factors that influence osteoblast differentiation because

they can initiate this process from uncommitted progenitors *in vitro* as well as *in vivo*.

Osteoblast commitment is mediated by the type I bone morphogenetic proteins receptor and involves the phosphorylation of specific transactivators (smad 1, 5 and possibly 9), which then oligomerize with smad 4 and translocate into the nucleus. These events induce an osteoblast specific transcription factor (OSF-2/cbfa-1/PEBP2aA/AML3), which in turn activates osteoblast-specific genes (6,7). Bone morphogenetic protein-2 and bone morphogenetic protein-4 are expressed during murine embryonal skeletogenesis (day 10-12) and act on cells isolated from murine limb buds to promote their differentiation into osteoblasts. In addition, bone morphogenetic protein-2 and bone morphogenetic protein-4 are involved in fracture healing, as evidenced by their expression in primitive mesenchymal cells and chondrocytes at the site of callus formation, as well as the ability of bone morphogenetic proteins to accelerate the fracture healing process when supplied exogenously.

Bone morphogenetic proteins play an essential role in the differentiation of cells that provide support for osteoclast development. Osteoclast development requires support from stromal/osteoblastic cells. Moreover, *in vivo*, osteoclastogenesis and osteoblastogenesis proceed simultaneously in most circumstances. This dependency is mediated by a membrane bound cytokine-like molecule (osteoprotegerin ligand/RANK ligand) present in mesenchymal cells which binds to a specific receptor on osteoclast progenitor cells. Such binding is essential, and together with M-CSF, sufficient, for osteoclastogenesis.

The adverse effects of hypercortisolism on bone have been recognized for over 60 years, but the precise cellular and molecular basis of these changes has remained elusive. Today, the iatrogenic form of the disease has become far more common than Cushing's syndrome
5 and glucocorticoid-induced osteoporosis is now third in frequency following post-menopausal and senile osteoporosis.

Bone loss due to glucocorticoid excess is diffuse, affecting both cortical and cancellous bone, but has a predilection for the axial skeleton. Spontaneous fractures of the vertebrae or ribs are, therefore,
10 often presenting manifestations of the disorder. A cardinal feature of glucocorticoid-induced osteoporosis is decreased bone formation. In addition, patients receiving long-term glucocorticoid therapy sometimes develop collapse of the femoral head (osteonecrosis), but the mechanism underlying this is uncertain. Decreased bone formation, and *in situ*
15 death of isolated segments of the proximal femur suggest that glucocorticoid excess may alter the birth and death of bone cells. Defective osteoblastogenesis has been reported to be linked to reduced bone formation and age-related osteopenia in the SAMP6 mouse. Besides the relationship between aberrant osteoblast production and
20 osteoporosis, it has been recently shown that a significant proportion of osteoblasts undergo apoptosis, which raises the possibility that the premature or more frequent occurrence of osteoblast apoptosis could contribute to incomplete repair of resorption cavities and loss of bone.

Once osteoblasts have completed their bone-forming
25 function, they either die by apoptosis, become entrapped in bone matrix and become osteocytes, or remain on the surface as lining cells. Previous studies have demonstrated that the number of osteoblasts is a critical determinant of bone formation, and that the osteopenic effects

of glucocorticoids are due, at least in part, to acceleration of osteoblast apoptosis and stimulation of osteocyte apoptosis.

While several agents are capable of decreasing bone resorption and halting further bone loss in osteopenic states, the ideal
5 drug would be an anabolic agent that increases bone mass by rebuilding bone. It is well established that daily injections of low doses of parathyroid hormone (PTH), an agent better known for its role in calcium homeostasis, increases bone mass in animals and humans (5) as
10 does the PTH-related protein (PTHrP), the only other known ligand of the PTH receptor (6). The mechanism of these anabolic effects, however, has not been established.

The prior art is deficient in methods of inhibiting apoptosis of osteoblasts and osteocytes. The present invention fulfills this long-standing need and desire in the art.

15

SUMMARY OF THE INVENTION

20

Intermittent PTH administration increases bone mass, but
the mechanism of this effect has remained heretofore unknown. Daily
PTH injections in mice either with normal bone mass or osteopenia due
to defective osteoblastogenesis increased bone formation without
25 affecting the generation of new osteoblasts. Instead, PTH did increase the life span of mature osteoblasts by preventing their apoptosis, an

effect reproduced *in vitro*. Increasing the work performed by a cell population to augment tissue mass by suppressing apoptosis represents a novel biologic paradigm for regenerating tissues; and could provide a pharmacotherapeutic strategy for rebuilding bone in patients with
5 established osteopenia.

Evidence is presented herein that human parathyroid hormone 1-34 [hPTH(1-34)] exerts anti-apoptotic effects on osteoblasts when administered in an intermittent fashion to mice *in vivo*. The present invention also provides evidence that bovine PTH(1-34)
10 [bPTH(1-34)] prevents glucocorticoid-induced apoptosis of osteoblastic and osteocytic cells *in vitro*.

One object of the present invention is to provide methods for screening compounds that prevent osteoblast apoptosis, thereby stimulating bone formation and/or restoring bone in osteopenic
15 individuals, or preventing bone loss caused by agents such as glucocorticoids.

In an embodiment of the present invention, there is provided a method of reducing the number of osteoblasts undergoing apoptosis in an individual in need of such treatment, comprising the
20 step of: administering a therapeutic dose of human parathyroid hormone [hPTH(1-34)] to said individual, wherein administration of human parathyroid hormone [hPTH(1-34)] results in a reduction in the number of osteoblasts undergoing apoptosis, thereby reducing bone loss and/or stimulating bone formation in said individual.

25 In another embodiment of the present invention, there is provided a method of screening compounds that stimulate bone formation, comprising the steps of: (a) contacting osteoblast cells with a test compound; (b) determining the number of said cells undergoing

apoptosis; and (c) comparing the number of apoptotic cells with osteoblast cells that have not been contacted with said compound, wherein fewer apoptotic cells following contact with said compound than in the absence of said contact indicates that said compound inhibits
5 apoptosis resulting in stimulation of bone formation.

In yet another embodiment of the present invention, there is provided a method of screening for compounds that decrease bone loss, comprising the steps of: (a) treating osteoblast cells with a glucocorticoid; (b) contacting said osteoblast cells with a test compound;
10 (c) determining the number of said osteoblast cells undergoing apoptosis; and (d) comparing the number of apoptotic cells with osteoblast cells that have been treated with said glucocorticoid but were not contacted with said test compound, wherein fewer apoptotic cells following contact with said test compound than in the absence of said
15 contact with said test compound indicates that said compound inhibits apoptosis of osteoblast cells thereby reducing bone loss.

Other and further aspects, features, and advantages of the present invention will be apparent from the following description of the presently preferred embodiments of the invention. These embodiments
20 are given for the purpose of disclosure.

BRIEF DESCRIPTION OF THE DRAWINGS

25 So that the matter in which the above-recited features, advantages and objects of the invention, as well as others which will become clear, are attained and can be understood in detail, more

particular descriptions of the invention briefly summarized above may be had by reference to certain embodiments thereof which are illustrated in the appended drawings. These drawings form a part of the specification. It is to be noted, however, that the appended
5 drawings illustrate preferred embodiments of the invention and therefore are not to be considered limiting in their scope.

Figure 1 shows glucocorticoid-induced apoptosis of osteoblastic cells inhibited by the specific caspase-3 inhibitor, DEVD.

Figure 2 shows that parathyroid hormone blocks
10 glucocorticoid-induced, but not TNF α -induced, apoptosis of osteoblastic cells.

Figure 3 shows that parathyroid hormone blocks glucocorticoid-induced, but not TNF α -induced, apoptosis of MLO-Y4 osteocytes.

Figure 4 shows that PTH fails to stimulate
15 osteoblastogenesis.

Figure 5 shows the BMD changes in PTH-treated mice.

Figure 6 shows that PTH stimulates osteoblast and osteocyte number as well as bone formation rate.

Figure 7 shows that bPTH(1-34) blocks glucocorticoid-induced apoptosis and bPTH(3-34) prevents the anti-apoptotic effect of
20 1-34 PTH.

Figure 8 shows that PTH blocks glucocorticoid-induced apoptosis of osteoblastic cells.

Figure 9 shows that bPTH(1-34) blocks glucocorticoid-induced apoptosis of MLO-Y4 osteocytes and bPTH(3-34) prevents the anti-apoptotic effect of 1-34 PTH.

Figure 10 shows that PTH and the cAMP analog, DBA, block glucocorticoid-induced apoptosis of MLO-Y4 osteocytes.

Figure 11 shows the effect of PTH on BMD. **Figure 11A**, Each point represents the mean (\pm s.d.) change in hindlimb BMD from base line. * $P < 0.05$ vs. vehicle established using a mixed effects longitudinal ANOVA model (Proc mixed, SAS, Cary, NC) to allow specification of the covariance structure. **Figure 11B**, Mean (\pm s.d.) BMD of hindlimb of SAMR1 and SAMP6 mice prior to ("initial") and after ("final") 28 days of treatment with hPTH(1-34). * $P < 0.05$ vs. initial by paired t-test; $P < 0.05$ vs. SAMR1 by Student's t-test.

Figure 12 shows distal femoral cancellous bone viewed with polarized light to reveal lamellar architecture. Arrows indicate osteocytes. Original magnification = 200X.

Figure 13 shows the mechanism and signal specificity of the suppressive effect of PTH on apoptosis in cultures of osteoblastic and osteocytic cells. **Figure 13A**, Inhibition of dexamethasone-induced apoptosis of calvaria cells and MLO-Y4 cells by PTH. Original magnification 400X. Insets: % of cells undergoing apoptosis determined from evaluation of 200 cells in randomly selected fields. **Figure 13B**, Cells (10^4 per cm^2) were incubated for 1 hour in vehicle (Veh) or 10^{-8} M bPTH(1-34), and then for an additional 6 hours in the absence ("basal") or presence of 5×10^{-5} M etoposide ("etop"), 10^{-7} M dexamethasone ("dex"), or 10^{-9} M TNF. **Figure 13C**, Osteoblastic calvaria cells were cultured for 1 hour in vehicle or the indicated log molar concentrations of bPTH(1-34), bPTH(3-34) or DB-cAMP, and then for an additional 6

hours in the absence or presence of 10^{-7} M dexamethasone. Adherent cells were released by digestion with trypsin-EDTA, combined with nonadherent cells, and apoptotic cells enumerated by trypan blue staining (7). Bars represent the mean (\pm s.d.) of 3 independent measurements. Cell death induced by etoposide, dexamethasone and TNF was blocked by DEVD-CHO, a cell permeable inhibitor of caspases required for the execution phase of apoptosis (21). Data were analyzed by ANOVA. Etoposide, dexamethasone, and TNF caused a significant ($p < 0.05$) increase in apoptosis in cultures containing vehicle. * $p < 0.05$ vs. vehicle (A), or vs. dexamethasone alone (B).

DETAILED DESCRIPTION OF THE INVENTION

Intermittent PTH administration increases bone mass, but the mechanism of this effect has remained heretofore unknown. Daily PTH injections in mice either with normal bone mass or osteopenia due to defective osteoblastogenesis increased bone formation without affecting the generation of new osteoblasts. Instead, PTH did increase the life span of mature osteoblasts by preventing their apoptosis, an effect reproduced *in vitro*. Increasing the work performed by a cell population to augment tissue mass by suppressing apoptosis represents a novel biologic paradigm for regenerating tissues; and could provide a pharmacotherapeutic strategy for rebuilding bone in patients with established osteopenia.

Evidence is presented herein that human parathyroid hormone 1-34 [hPTH(1-34)] exerts anti-apoptotic effects on osteoblasts when administered in an intermittent fashion to mice *in vivo*. Evidence

is also presented herein that bovine PTH(1-34) [bPTH(1-34)] prevents glucocorticoid-induced apoptosis of osteoblastic and osteocytic cells *in vitro*. These observations demonstrate that the previously established anabolic effects of parathyroid hormone on the skeleton are mediated
5 by its ability to postpone osteoblast apoptosis, as opposed to a stimulatory effect on osteoblastogenesis. Results presented herein also demonstrate that the ability of parathyroid hormone to prevent glucocorticoid-induced osteoblast and osteocyte apoptosis is due to direct interference with a private death pathway that occurs prior to
10 activation of the final steps of apoptotic mechanism such as activation of the protease caspase-3.

The present invention is directed towards methods of screening agents for the ability to inhibit apoptosis of osteoblasts and osteocytes, thereby identifying agents capable of stimulating and/or
15 restoring bone formation, or preventing bone loss due to treatment with agents such as glucocorticoids.

The present invention is directed to a method of reducing the number of osteoblasts undergoing apoptosis in an individual in need of such treatment, comprising the step of: administering a therapeutic
20 dose of human parathyroid hormone [hPTH(1-34)] to said individual, wherein administration of human parathyroid hormone [hPTH(1-34)] results in a reduction in the number of osteoblasts undergoing
~~apoptosis, thereby preventing bone loss and/or stimulating bone~~
formation in said individual. In one aspect, the individual is osteopenic.
25 Preferably, the individual is selected from the group consisting of an individual currently being treated with one or more glucocorticoid compounds and an individual previously treated with one or more glucocorticoid compounds. Although any route of administration of

human parathyroid hormone [hPTH(1-34)] may be used, systemic, oral, intravenous, nasal spray and inhalation are preferred. Generally, the human parathyroid hormone [hPTH(1-34)] is administered in a dose of from about 10 µg/kg of body weight to about 1000 µg/kg of body weight.

The present invention is also directed to a method of screening compounds that stimulate bone formation, comprising the steps of: (a) contacting osteoblast cells with said compound; (b) determining the number of said cells undergoing apoptosis; and (c) comparing the number of apoptotic cells with osteoblast cells that have not been contacted with said compound, wherein fewer apoptotic cells following contact with said compound than in the absence of said contact indicates that said compound inhibits apoptosis resulting in stimulation of bone formation. Generally, in this method, the contacting of said osteoblast cells is selected from the group consisting of *in vitro* osteoblast cells and an *in vivo* murine animal model. Representative *in vivo* murine animal models are the SAMP6 mouse and the SAMR1 mouse. Generally, the stimulation of bone formation is confirmed by methods known to those having ordinary skill in this art such as measuring BMD, measuring cancellous bone area, measuring cancellous bone formation rate, measuring the number of osteoblasts per cancellous bone perimeter and measuring the number of osteocytes per bone area in said murine animal model following said contact with said compound compared with a murine animal model in the absence of said contact with said compound. The determination of apoptotic cells may be by microscopy of stained cells, TUNEL, Hoescht 33258 dye and video image analysis.

The present invention is also directed to a method of screening for compounds that decrease bone loss, comprising the steps of: (a) treating osteoblast cells with a glucocorticoid; (b) contacting said osteoblast cells with a test compound; (c) determining the number of
5 said osteoblast cells undergoing apoptosis; and (d) comparing the number of apoptotic cells with osteoblast cells that have been treated with said glucocorticoid but were not contacted with said test compound, wherein fewer apoptotic cells following contact with said test compound than in the absence of said contact with said test
10 compound indicates that said compound inhibits apoptosis of osteoblast cells thereby reducing bone loss. The contacting of the osteoblast cells may be *in vitro* osteoblast cells or in an *in vivo* murine animal model. Representative *in vivo* murine animal models include the SAMP6 mouse and the SAMR1 mouse. The determination of apoptotic cells may be by
15 microscopy of stained cells, TUNEL, Hoescht 33258 dye and video image analysis.

It is specifically contemplated that pharmaceutical compositions may be prepared using the parathyroid hormone of the present invention. In such a case, the pharmaceutical composition
20 comprises the parathyroid hormone of the present invention and a pharmaceutically acceptable carrier. A person having ordinary skill in this art would readily be able to determine, without undue experimentation, the appropriate dosages and routes of administration
of this parathyroid hormone of the present invention. When used *in*
25 *vivo* for therapy, the parathyroid hormone of the present invention is administered to the patient or an animal in therapeutically effective amounts, i.e., amounts that increase or stimulate bone formation. It will normally be administered parenterally, preferably subcutaneously by

nasal spray or inhalation, but other routes of administration will be used as appropriate.

5 The dose and dosage regimen of the parathyroid hormone will depend upon the nature of the disease, the characteristics of the particular parathyroid hormone, *e.g.*, its therapeutic index, the patient, the patient's history and other factors. The amount of parathyroid hormone administered will typically be in the range of about 10 to about 1000 $\mu\text{g/kg}$ of patient weight. The schedule will be continued to optimize effectiveness while balanced against negative effects of treatment. See Remington's Pharmaceutical Science, 17th Ed. (1990) Mark Publishing Co., Easton, Penn.; and *Goodman and Gilman's: The Pharmacological Basis of Therapeutics* 8th Ed (1990) Pergamon Press; which are incorporated herein by reference. For parenteral administration, parathyroid hormone will most typically be formulated in a unit dosage injectable form (solution, suspension, emulsion) in association with a pharmaceutically acceptable parenteral vehicle. Such vehicles are preferably non-toxic and non-therapeutic. Examples of such vehicles are water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Nonaqueous vehicles such as fixed oils and ethyl oleate may also be used. Liposomes may be used as carriers. The vehicle may contain minor amounts of additives such as substances that enhance isotonicity and chemical stability, *e.g.*, buffers and preservatives. Parathyroid hormone will typically be formulated in such vehicles at concentrations of about 10 $\mu\text{g/ml}$ to 1000 $\mu\text{g/ml}$.

25 The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion:

EXAMPLE 1

In vitro effects of PTH

The number of osteoblasts, a critical determinant of bone formation and bone mass, depends both on the birth rate of these cells, which reflects the frequency of cell division of mesenchymal precursors, and on their life span, which reflects the timing of death by apoptosis. *In vivo* evidence indicates that intermittent administration of parathyroid hormone(1-34) increases bone formation and BMD in mice and that these changes are associated with decreased osteoblast and osteocyte apoptosis, but not with increased production of progenitors in the bone marrow.

To determine the mechanism of such actions, the effects of parathyroid hormone(1-34) on the apoptosis of cultured osteoblastic cells isolated from neonatal murine calvaria and the MLO-Y4 osteocyte cell line (provided by L. Bonewald) were examined. Chromatin condensation, nuclear fragmentation, and DNA degradation--cardinal features of apoptotic cells--were monitored by microscopic examination of cells stained with the DNA dye Hoescht 33258, or stably transfected with green fluorescent protein gene containing a nuclear localization sequence, and by DNA end labeling (TUNEL). Enumeration of apoptotic cells was performed by trypan blue staining, and correlated closely with morphologic changes and TUNEL.

In both osteoblast and osteocyte cultures, 15% of the cells were apoptotic 6 hours after addition of 100 nM dexamethasone, as compared to 4% in cultures without the steroid. This effect was completely prevented by 10 nM parathyroid hormone(1-34) or 1 mM dibutyryl-cAMP added 1 hour prior to addition of dexamethasone. The parathyroid hormone effect did not involve cytokines with anti-

apoptotic properties, as neutralizing antibodies against IL-6, IL-11 or LIF did not interfere with this phenomenon. In contrast to dexamethasone-induced apoptosis, parathyroid hormone had no influence on TNF-induced apoptosis. These findings are consistent with *in vivo* evidence demonstrating that the anabolic effects of parathyroid hormone are due to its anti-apoptotic effects on osteoblasts and osteocytes; and that parathyroid hormone interferes directly with a private apoptosis pathway at a site(s) upstream of the induction of the degradation phase of apoptosis which is executed by caspase-3.

10

EXAMPLE 2

Calvaria and MLO-Y4 cells

Osteoblastic calvaria cells (9) were cultured in α MEM (Gibco-BRL, Grand Island, NY) supplemented with 10% FBS (Sigma Chemical Co., St. Louis, MO). Murine osteocyte-like MLO-Y4 cells stably transfected with EGFP were cultured on collagen coated plates in (MEM supplemented with 5% FBS and 5% bovine calf serum. Cultures were maintained for 6 hours in the presence of 10^{-7} M dexamethasone without or with preincubation for 1 hour with 10^{-8} M bPTH(1-34) and fixed in neutral buffered formalin. The pyknotic fragmented nuclei (arrows) typical of apoptotic cells were visualized with Hoescht 33258 fluorescent dye (Polysciences, Inc., Bayshore, NY), used at a concentration of 1 μ g/ml in 0.5 M NaCl, 10 mM Tris-HCl, 1 mM EDTA, pH 7.4) in osteoblastic calvaria cells, and by EGFP fluorescence in MLO-Y4 osteocytes.

25

Osteoblastic cells were isolated from calvaria of 3- to 6-day-old C57/B1 mice by sequential collagenase digestion. Cells were cultured for 5-8 days in α MEM supplemented with 10% FBS and frozen in liquid

N₂ until use. MLO-Y4 cells (provided by Dr. L. Bonewald, University of Texas Health Science Center at San Antonio, San Antonio, TX) were transduced with the pLXSN retroviral vector containing a construct encoding enhanced green fluorescent protein (Clontech, Palo Alto, CA) with the SV40 large T antigen nuclear localization sequence [D. Kalderon et al., Cell 39, 499 (1984)] attached to the carboxyterminus. Stably transduced cells were selected for neomycin resistance using G418 (Sigma, St. Louis, MO).

10

EXAMPLE 3

Mice

4-5 month old male or female SAMR1 and SAMP6 were given daily injections of vehicle (0.9% saline, 0.01 mM β -mercaptoethanol, 0.1 mM acetic acid) or 400 ng/g body weight of hPTH(1-34) (Bachem, Torrance, CA) dissolved in vehicle (n=6-7 per group). Mice were fed a standard rodent diet (Agway RMH 3000, Arlington Heights, IL) *ad libitum*. The BMD of the spine and hindquarters was determined one day prior to initiation of the experiment (baseline scan) and at weekly intervals thereafter using dual-energy X-ray absorptiometry (QDR 2000, Hologic, Inc.) as described previously (3). The evaluation of each scan was based on the exact positioning and region of interest placement of the baseline scan using the "Compare" technique (4).

25

EXAMPLE 4

Experimental Methods

To determine the effect of PTH on osteoblast formation, function and fate, mice from the experiment shown in Figure 11 were

killed on day 28. The animals had been pretreated with tetracycline (5 $\mu\text{g/g}$, s.c.) on day 19 and 26. Osteoblast progenitors were measured using marrow cells from one femur. Cells from each animal were cultured separately at 2.5×10^6 per 10 cm^2 well and maintained for 28
5 days in phenol red-free (MEM containing 15% preselected FBS (HyClone, Logan, UT) and 1 mM ascorbate-2-phosphate (18). Von Kossa's method was used to visualize and enumerate colonies containing mineralized bone matrix. Because each colony is derived from a single osteoblast progenitor, the colony forming unit osteoblast (CFU-OB), the number of
10 CFU-OB colonies reflects the number of osteoblast progenitors present in the original bone marrow isolate. The remaining femur and lumbar vertebrae were fixed in 4°C Millonig's phosphate-buffered 10% formalin, pH 7.4 and embedded undecalcified in methyl methacrylate.

Measurements of the femoral length and the midshaft
15 diaphyseal cortical width were made with a digital caliper at a resolution of 0.01 mm (Mitutoyo Model #500-196, Ace Tools, Ft. Smith, AR). Histomorphometric examination of five micron thick bone sections were performed using a computer and digitizer tablet (OsteoMetrics Inc. Version 3.00, Atlanta, GA) interfaced to a Zeiss Axioscope (Carl Zeiss,
20 Inc., Thornwood, NY) with a drawing tube attachment (4). Measurements were confined to the secondary spongiosa of the distal femur. The terminology and units used are those recommended by the Histomorphometry Nomenclature Committee of the American Society for Bone and Mineral Research (19). The rate of bone formation
25 ($\mu\text{m}^2/\mu\text{m/d}$) was calculated from the extent of bone surface labeled with tetracycline (visualized by fluorescence under UV illumination) and the distance between the labels in areas where two labels are present.

Osteoid was recognized by its distinct staining characteristics and osteoblasts were identified as plump cuboidal cells on osteoid surfaces.

Apoptotic osteoblasts were detected in sections of nondecalcified vertebral bone by the TUNEL reaction (TdT-mediated dUTP nick end labeling) using reagents from Oncogene (Cambridge, MA) (4,7). Briefly, sections were incubated in 0.5% pepsin in 0.1 N HCl for 20 minutes at 37°C, rinsed with TBS and then incubated in 30% H₂O₂ in methanol for 5 minutes, and rinsed again. To improve the sensitivity of the reaction, sections were subsequently incubated for 1-2 minutes with 0.15% CuSO₄ in 0.9% NaCl (20). TUNEL-positive hypertrophic chondrocytes were observed at the bottom of the growth plates serving as an internal positive control for each bone section. The prevalence of osteoblast apoptosis was determined by inspecting 1190 and 852 osteoblasts in sections from vehicle-treated and 2514 and 1490 osteoblasts in PTH-treated SAMR1 and SAMP6 mice, respectively. For the determination of osteocyte apoptosis, 1579 and 1714 osteocytes were evaluated in vehicle-treated and 2930 and 2259 osteocytes in PTH-treated SAMR1 and SAMP6 mice, respectively. Wall width represents the amount of bone synthesized by a team of osteoblasts and was measured as the distance from the bone surface to a cement line in the underlying bone demarcating the site at which bone formation began. Osteocytes were identified inside lacunae in mineralized bone. Osteoclasts were recognized by staining with tartrate resistant acid phosphatase.

The decrease in the number of apoptotic osteoblasts in PTH-treated mice was confirmed in a second set of bone sections stained with the standard TUNEL technique (4,7), as opposed to the modified TUNEL method used for the data presented in the text and Table 1, in

which CuSO_4 is added subsequent to peroxidase staining to intensify the chromogen so as to allow detection of DNA degradation as early as possible (20). Using the standard TUNEL technique, the prevalence of apoptotic osteoblasts in PTH-treated mice was 0.017% (1 out of 5,900
5 osteoblasts inspected in 36 sections taken from 12 mice: 6 SAMR1 and 6 SAMP6) compared to 0.37% in the vehicle-treated controls (12 out of 3,250 osteoblasts inspected in 39 sections taken from 13 mice, 6 SAMR1 and 7 SAMP6); $p < 0.001$ vs. PTH-treated animals by logistic regression (LogXact, Cytel Corp. Cambridge, MA). The increase in the absolute
10 number of TUNEL-labeled cells observed with the modified as compared to the standard technique is consistent with the contention that the former procedure allows visualization of cells undergoing the DNA degradation phase at an earlier stage. Prolongation or shortening of the time that apoptosis can be observed in a specimen as a result of using a
15 more or less sensitive detection method must be taken into consideration when comparing estimates of the prevalence of the phenomenon in different studies (4,7). This variability of the duration of the apoptosis process in different cell types can account for reports estimating the TUNEL-labeled phase of apoptosis from as little as 1.5 to
20 as much as 48 hours.

EXAMPLE 5

In vivo effects on mice of bPTH

25 Intermittent administration of parathyroid hormone exerts an anabolic effect on the skeleton of animals and humans, most likely due to an increase in the number of osteoblasts. This number depends both on the birth rate (reflecting the frequency of division of

mesenchymal progenitors) and the life span (reflecting the timing of apoptosis). The present invention examines the effects of intermittent parathyroid hormone administration in mice with either normal (SAMR1) or defective (SAMP6) osteoblastogenesis at four months of age, 5 a time at which both strains have achieved peak bone mass.

Mice (6-7 per group) were given daily subcutaneous injections of 400 ng bovine parathyroid hormone (1-34) per gram of body weight or vehicle for a period of 4 weeks. BMD was monitored weekly by DEXA. One femur was used for tetracycline based dynamic 10 histomorphometry and the other for determination of osteoblast progenitors in *ex vivo* bone marrow cultures. Spine and hindquarter BMD increased gradually in parathyroid hormone-treated mice of either strain reaching 4% and 15%, respectively, over the pretreatment values by 4 weeks. Parathyroid hormone also increased cancellous bone area and bone formation rate (2-3 fold), as well as the number of osteoblasts 15 per cancellous bone perimeter and the number of osteocytes per bone area (2-fold) in both strains.

These changes could not be accounted for by hypertrophy of lining cells and their subsequent conversion to osteocytes because the 20 increased osteocyte density in the expanded cancellous bone area was much too great. Unlike the increase in mature cell numbers, the number of CFU-OB formed per 10^6 marrow cells in *ex vivo* bone marrow cultures did not change in either strain (SAMR1: vehicle= 34 ± 7 , PTH= 34 ± 9 ; SAMP6: vehicle= 17 ± 2 , PTH= 21 ± 5). Parathyroid hormone did, 25 however, decrease osteoblast apoptosis.

As detected by DNA end-labeling (TUNEL), 0.33% and 0.40% of osteoblasts were apoptotic in bone of SAMR1 and SAMP6 mice, respectively (N=3250), whereas only 0.02% of the 4200 osteoblasts

examined in parathyroid hormone-treated mice were apoptotic ($P < 0.02$ by z-test). Based on an osteoblast lifetime of 300 hours, and a 3 hour duration of apoptosis, it was calculated that parathyroid hormone postponed apoptosis of the 30-40% of osteoblasts that would normally undergo this process during bone remodeling. These findings indicate that suppression of osteoblast apoptosis, rather than increased osteoblastogenesis, is the mechanism by which intermittent administration of parathyroid hormone stimulates bone formation. This effect is sufficient to account for the increase in the number of osteoblast and osteocytes and, thereby, the anabolic effect of the hormone.

EXAMPLE 6

In vivo effects of hPTH on mice

Daily subcutaneous injections of hPTH (1-34) over a four week period progressively increased bone mineral density (BMD) in adult mice with normal bone mass (SAMR1) or in mice with osteopenia (3) due to impaired osteoblastogenesis and decreased bone formation (SAMP6) (Figure 11A). This effect was greater in the hindlimbs than in the spine and did not involve bone growth as reflected by the lack of change in the length of the femur or its width at the diaphysis (Table 1). Remarkably, the increase in BMD was similar in the two strains, even though the baseline values were different (Figure 11B).

Consistent with the BMD increase, histomorphometric analysis of sections of cancellous bone from the distal femurs of mice of either strain treated with PTH showed increased cancellous bone area that correlated with the increase in hindlimb BMD ($r = 0.53$, $P < 0.001$). The latter could be explained by the increase in the number of

osteoblasts covering the bone surface and by the increased rate of bone formation (Table 1). As expected from these changes, the amount of osteoid, the matrix produced by osteoblasts, was also increased, as was the amount of bone estimated to be produced by each team of
5 osteoblasts (wall width). The number of osteoclasts on the cancellous bone surface was not changed with PTH treatment, indicating that bone resorption and turnover were not affected by the hormone. The newly formed bone had normal lamellar architecture as opposed to woven bone seen in severe hyperparathyroidism (Figure 12).

10 As osteoblasts are short-lived cells (approximately 200 hours in mice) (4,7), the increase in the number of osteoblasts seen in the PTH-treated mice could result from either an increase in the formation of new osteoblasts or the prolongation of their life span. Enumeration of osteoblast progenitors in ex vivo bone marrow cell
15 cultures, a reliable index of *de novo* osteoblastogenesis (3), showed no difference between PTH and vehicle-treated animals (Table 1). The lack of effect of PTH on osteoblast progenitors was documented in the normal mouse strain (SAMR1) as well as in the strain with the diminished baseline osteoblastogenesis (SAMP6), clearly demonstrating
20 that an increase in the formation of new osteoblasts could not account for the increased osteoblast numbers seen in both strains.

Strikingly, however, the percentage of osteoblasts undergoing apoptosis, as determined by TUNEL-labeling, was greatly decreased in animals of either strain receiving PTH (Table 1).
25 Specifically, the average number of apoptotic osteoblasts, determined separately for each animal, was $0.4 \pm 0.5\%$ (range 0-1.4%, n=6) for PTH-treated SAMR1 as compared to $1.7 \pm 1.0\%$ (range 0.5-3.2%, n=6) for vehicle-treated SAMR1, $p < 0.05$. Similarly, the average number of

apoptotic osteoblasts in PTH-treated SAMP6 was $0.1 \pm 0.3\%$ (range 0-0.8%, n=6) as compared to $2.2 \pm 1.4\%$ (range 0.9-4.7%, n=7) for vehicle-treated SAMP6, $p < 0.05$ (8).

Table 1 shows the effect of PTH on osteoblast formation, function and fate. Mice from the experiment shown in Fig. 1 were killed on day 28. The animals had been pretreated with tetracycline (5 $\mu\text{g/g}$, s.c.) on day 19 and 26. Osteoblast progenitors were measured using marrow cells from one femur. The average number of nucleated cells obtained from the femur of PTH treated animals ($19.8 \pm 3.2 \times 10^6$ from SAMR1; $24.3 \pm 3.0 \times 10^6$ from SAMP6) was indistinguishable from animals receiving vehicle ($21.0 \pm 2.7 \times 10^6$ from SAMR1; $21.5 \pm 3.2 \times 10^6$ from SAMP6). The remaining femur and lumbar vertebrae were fixed and embedded undecalcified in methylmethacrylate (3,4,15). Femurs were used for histomorphometric analysis and vertebrae were used for apoptosis determinations. Because osteoblasts in remodeling bone comprise a team, they were identified as cuboidal cells in a row of at least three, lining the osteoid-covered trabecular perimeter. Osteocytes were identified inside lacunae of mineralized cancellous bone. For detection of apoptotic cells, sections were incubated with CuSO_4 to enhance staining of the peroxidase reaction production during the TUNEL procedure, as described in Methods. Osteoblasts and osteocytes exhibiting both brown staining due to TUNEL and the morphological feature of nuclear condensation were counted as apoptotic. With these precautions, TUNEL has been unequivocally associated with apoptosis of osteoblasts and osteocytes in bone (4,29,50). See Table 2 for a summary of apoptotic and non-apoptotic cell counts in individual animals. The data shown represent the mean (\pm s.d.) of each measurement determined from bones from each animal.

^A $P < 0.05$ vs. vehicle by one-tailed Students t-test. ^BTwo-way ANOVA was used to detect overall effects of PTH. ^C $P < 0.001$ vs. vehicle by GSK categorical general linear regression (26).

Table 2 shows the effect of PTH on apoptosis of osteoblasts and osteocytes in vertebral cancellous bone. Osteoblasts (OB) and osteocytes (OCT) were identified in sections of lumbar vertebrae, and those exhibiting both brown staining due to TUNEL and pyknotic nuclei were counted as apoptotic as described in Table 1. Results are from two separate TUNEL staining procedures. In the first, TUNEL was performed without CuSO_4 enhancement ("w/o Cu"), and data were pooled from animals from each group for statistical analysis because of the low number of apoptotic osteoblasts visualized with this method. In the second, CuSO_4 ("with Cu") was used to enhance TUNEL staining, and counts from each animal are shown. With the exception of the apoptotic osteocyte counts in the vehicle treated SAMP6 group, there were no significant differences among the animals within each group. Pooled data ("w/o Cu") were analyzed by logistic regression. ^A $P < 0.0001$ vs. vehicle. Data from individual animals were analyzed by GSK. ^B $P < 0.001$ vs. vehicle.

Table 1.

	SAMR1		SAM
	vehicle	PTH	vehicle
CFU-OB (# per 10 ⁶ marrow cells)	34 ± 7	34 ± 9	17 ± 3
Osteoblast perimeter (%)	7.1 ± 2.9	11.8 ± 6.8 ^A	5.7 ± 3.5
Apoptotic osteoblasts (%)	1.7 ± 1.0	0.4 ± 0.5 ^C	2.2 ± 1.4
Bone area (% of tissue area)	9.0 ± 4.2	23.2 ± 11.3 ^A	8.9 ± 2.9
Bone formation rate (μm/μm ² /d)	0.087 ± 0.039	0.361 ± 0.413 ^A	0.071 ± 0.010
Mineralizing perimeter (%)	8.92 ± 4.67	14.96 ± 4.82 ^A	6.56 ± 3.24
Mineral apposition rate (μm/d)	1.09 ± 0.43	1.14 ± 0.87	1.07 ± 0.23
Trabecular width (μm)	37.2 ± 11.0	56.7 ± 21.2 ^A	39.9 ± 9.1
Wall width (μm)	10.2 ± 2.5	13.4 ± 3.2 ^A	5.4 ± 0.9
Osteoid perimeter (%)	13.2 ± 7.8	17.4 ± 4.9	9.9 ± 5.5
Osteocyte areal density (# per bone area)	8.2 ± 3.1	14.8 ± 6.4 ^A	14.3 ± 5.7
Apoptotic osteocytes (%)	1.7 ± 0.5	0.2 ± 0.2 ^C	2.5 ± 2.0
Osteoclast perimeter (%)	1.3 ± 0.8	0.7 ± 0.8	2.3 ± 2.5
Femoral length (mm)	15.82 ± 0.51	16.14 ± 0.48	15.03 ± 0.66
Diaphyseal cortical width (mm)	0.59 ± 0.38	0.54 ± 0.13	0.56 ± 0.13

Table 2.

Group	Sample, or Mouse ID	Apop totic OB	Total OB Counte d	% Apop totic OB	Apop totic OCT	Total OCT Count ed	% Apopt otic OCT
SAMR1, Veh	Pooled (w/o Cu)	5	1500	0.3	-	-	-
	5-6 (with Cu)	5	271	1.8	7	368	1.9
	5-15	9	280	3.2	9	350	2.5
	5-17	6	258	2.3	4	240	1.6
	5-20	1	199	0.5	2	237	0.8
	5-14	1	113	0.9	4	244	1.6
	5-1	1	69	1.4	2	98	1.8
			Mean \pm s.d:	1.7 \pm 1.0			1.7 \pm 0.5
SAMR1, PTH	Pooled (w/o Cu)	0	3700	0 ^A	-	-	-
	5-7 (with Cu)	0	206	0	0	403	0
	5-8	1	328	0.3	1	477	0.3
	5-18	1	372	0.3	2	489	0.3
	5-2	3	206	1.4	2	618	1.4
	5-9	2	397	0.5	1	669	0.5
	5-11	0	151	0	0	262	0
			Mean \pm s.d:	0.4 \pm 0.5 ^B			0.2 \pm 0.2 ^B

SAMP6, Veh	Pooled (w/o Cu)	7	1750	0.4	-	-	-
	7-19 (with Cu)	6	180	3.4	9	204	4.3
	7-11	3	64	4.7	4	302	1.3
	7-6	1	114	0.9	10	169	5.7
	7-12	3	185	1.6	1	353	0.3
	7-17	2	109	1.8	9	342	2.6
	7-21	1	88	1.1	1	208	0.5
	7-24	2	113	1.8	11	384	2.8
			Mean \pm s.d:	2.2 \pm 1.4			2.5 \pm 2.0
SAMP6, PTH	Pooled (w/o Cu)	1	2200	0.05 ^A	-	-	-
	7-1 (with Cu)	0	289	0	3	500	0.6
	7-4	0	387	0	1	487	0.2
	7-7	3	400	0.8	2	350	0.7
	7-9	0	160	0	2	321	0.6
	7-16	0	120	0	1	293	0.3
	7-23	0	134	0	0	303	0
			Mean \pm s.d:	0.1 \pm 0.3 ^B			0.4 \pm 0.3 ^B

EXAMPLE 7

Effect of PTH on osteocytes

PTH-treated mice also exhibited increased osteocyte density - i.e. number per cancellous bone area (Table 1 and Figure 12).
5 Osteocytes are former osteoblasts that have completed their bone-forming function and are encased within lacunae of the mineralized bone matrix, one of the three possible fates of matrix synthesizing cells, the other two being apoptosis and conversion to lining cells. Hence, an increase in osteocyte density is consistent with, and can only be
10 accounted for by, a suppression of osteoblast apoptosis. Besides the effect on osteoblast apoptosis, intermittent PTH administration also inhibited osteocyte apoptosis (Table 1).

EXAMPLE 8

15 Anti-apoptotic effect of PTH

To determine whether the anti-apoptotic effect of PTH was due to direct action of the hormone on osteoblasts and osteocytes, as opposed to indirect actions mediated by compensatory changes, the effect of PTH on apoptosis was examined using cell cultures. Induction
20 of apoptosis by either etoposide or dexamethasone was attenuated by PTH in primary cultures of osteoblasts isolated from neonatal murine calvaria (9) whereas induction of apoptosis by TNF was not (Figure 13A,B). These findings were reproduced using murine osteoblastic MC3T3-E1 cells as well as human osteoblastic MG-63 cells (10). The
25 anti-apoptotic effect of PTH could be blocked by the PTH/PTHrP receptor antagonist bPTH(3-34) and was mimicked by dibutyryl-cAMP, indicating that it was mediated through the PTH/PTHrP receptor and

subsequent activation of adenylate cyclase (Figure 13C). PTH also prevented etoposide- and dexamethasone-induced apoptosis, but not TNF-induced apoptosis in an established murine osteocyte-like cell line, MLO-Y4 (11), stably transfected with the enhanced green fluorescent protein (EGFP) gene containing a nuclear localization sequence, (Figure 13A,B).

Summary

The data presented herein demonstrates that intermittent administration of PTH stimulates bone formation, not by increasing the proliferation of osteoblast precursors but by preventing osteoblast apoptosis - the fate of the majority of these cells under normal conditions (4, 7) - thereby prolonging the time spent in performing their matrix synthesizing function. The anti-apoptotic effect of PTH is exerted directly on osteoblasts, requires binding of the hormone to the PTH/PTHrP receptor, is mediated by cAMP-generated signals that interfere with some but not all death pathways, and occurs upstream of the common executing phase of apoptosis. Consistent with the results of the present studies in mice, the ability of intermittent administration of PTH to increase osteoblast numbers was not accompanied by an increase in the replication of osteoblast progenitors in the rat (12). Moreover, the demonstration of the ability of PTH to inhibit osteoblast apoptosis is in full agreement with the anti-apoptotic effect of PTHrP on chondrocytes during endochondral bone development (13).

Results of a clinical study have shown that daily subcutaneous injections of PTH is an effective treatment for glucocorticoid-induced osteoporosis (15). The decreased bone formation rate and wall thickness of trabeculae, indicators of diminished work by

osteoblasts and the *in situ* death of portions of bone that characterize glucocorticoid-induced osteoporosis can be accounted for by a suppressive effect of glucocorticoids on osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes (4). The
5 elucidation of the anti-apoptotic effects of PTH *in vivo* along with the evidence that PTH antagonizes the pro-apoptotic effects of glucocorticoids *in vitro* are in full agreement with the published clinical observations. Furthermore, they provide both a mechanistic
10 explanation for the efficacy of PTH in glucocorticoid-induced osteoporosis as well as compelling evidence that its anti-apoptotic properties make PTH a rational pharmacotherapeutic choice for this condition.

Apart from decreased cell death, another potential source of new osteoblasts is the lining cells that cover quiescent bone surfaces
15 (16). These cells were once matrix synthesizing osteoblasts, and have escaped apoptosis or encasement within bone as osteocytes to remain on the bone surface. It has been suggested that PTH can stimulate lining cells to undergo hypertrophy and to resume matrix synthesis (12,17). Such hypertrophy was not observed, but a contribution from
20 this mechanism cannot be excluded from the results of the present report. Nevertheless, the magnitude of the anti-apoptotic effect of PTH makes it unnecessary to invoke another explanation for increased bone formation.

In conclusion, the data presented herein demonstrate that
25 prevention of osteoblast apoptosis is the principal mechanism for the anabolic effects of PTH on bone. Increasing the work-output of a cell population by suppressing apoptosis represents a novel biologic paradigm for regenerating tissues in general and a rational

pharmacotherapeutic strategy for rebuilding bone in particular. PTH, and possibly PTH mimetics and non-peptide inhibitors of private apoptotic pathways in osteoblasts, should provide much needed therapies for osteopenias, in particular those in which osteoblast
5 progenitors are low, such as age-related and glucocorticoid induced osteoporosis.

The following references were cited herein:

1. S.C. Manolagas & R.L. Jilka, N.Engl.J.Med. 332, 305 (1995).
2. R.L. Jilka et al., Science 257, 88 (1992).
- 10 3. R.L. Jilka et al., J.Clin.Invest. 97, 1732 (1996).
4. R.S. Weinstein et al., ibid., 102, 274 (1998).
5. D.W. Dempster et al., Endocr.Rev. 14, 690 (1993); J. Reeve et al., Lancet 1(7968), 1035 (1976); J. Reeve et al., Br.Med.J. 280, 1340 (1980); C.S. Tam et al., Endocrinology 110, 506 (1982); J.S. Finkelstein et
15 al., JAMA 280, 1067 (1998).
6. A.F. Stewart, Bone 19, 303 (1996); B.H. Vickery et al., J. Bone Miner. Res. 11, 1943 (1996).
7. R.L. Jilka et al., J.Bone Miner.Res. 13, 793 (1998).
8. W. Bursch et al., Carcinogenesis 11, 847 (1990); M. Pompeiano et
20 al., Cell Death Differ. 5, 702 (1998).
9. R.L. Jilka, Bone. 7, 29 (1986).
10. H. Sudo et al., J.Cell Biol. 96, 191 (1983); R.T. Franceschi et al., J.Biol.Chem. 263, 18938 (1988).
11. Y. Kato et al., J.Bone Miner.Res. 12, 2014 (1997).
- 25 12. H. Dobnig & R.T. Turner, Endocrinology 136, 3632 (1995).
13. M. Amling et al, J.Cell Biol. 136, 205 (1997); K. Lee et al., Endocrinology 137, 5109 (1996).
14. E.M. Aarden et al., J. Cellular Biochem. 55, 287 (1994).

15. N.E. Lane et al., J.Clin.Invest. 102, 1633 (1998).
16. S.C. Miller & W.S.S. Jee, Bone. Volume 4: Bone Metabolism and Mineralization, B.K. Hall, Ed. (CRC Press, Boca Raton, 1992), p. 1.
17. D. Leaffer et al., Endocrinology 136, 3624 (1995).
- 5 18. R.L. Jilka et al., J.Clin.Invest. 101, 1942 (1998).
19. A.M. Parfitt et al., J.Bone Miner.Res. 2, 595 (1987).
20. S. Hsu & E. Soban, J. Histochem. Cytochem. 30, 1079 (1982); B.G. Short et al., ibid, 45, 1299 (1997).
21. S.C. Wright et al., J.Exp.Med. 186, 1107 (1997); N.A. Thornberry &
10 Y. Lazebnik, Science 281, 1312 (1998).

Any patents or publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains. Further, these patents and publications are incorporated by reference herein to the same extent as if each
15 individual publication was specifically and individually indicated to be incorporated by reference.

One skilled in the art will appreciate readily that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those objects, ends and
20 advantages inherent herein. The present examples, along with the methods, procedures, treatments, molecules, and specific compounds described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to
25 those skilled in the art which are encompassed within the spirit of the invention as defined by the scope of the claims.

WHAT IS CLAIMED IS:

1. A method of reducing the number of osteoblasts undergoing apoptosis in an individual in need of such treatment,
5 comprising the step of:

administering a therapeutic dose of human parathyroid hormone [hPTH(1-34)] to said individual, wherein administration of human parathyroid hormone [hPTH(1-34)] results in a reduction in the number of osteoblasts undergoing apoptosis, thereby preventing bone
10 loss and/or stimulating bone formation in said individual.

2. The method of claim 1, wherein said individual is osteopenic.

15 3. The method of claim 1, wherein said individual is selected from the group consisting of an individual currently being treated with one or more glucocorticoid compounds and an individual previously treated with one or more glucocorticoid compounds.

20 4. The method of claim 1, wherein said administration is selected from the group consisting of systemic, oral, intravenous, nasal spray and inhalation.

5. The method of claim 1, wherein said human parathyroid hormone [hPTH(1-34)] is administered in a dose of from
25 about 10 µg/kg to about 1000 µg/kg.

6. A method of screening for a compound that stimulates bone formation, comprising the steps of:

- (a) contacting osteoblast cells with a test compound;
- 5 (b) determining the number of said cells undergoing apoptosis; and
- (c) comparing the number of apoptotic cells with osteoblast cells that have not been contacted with said compound, wherein fewer apoptotic cells following contact with said compound
10 than in the absence of said contact indicates that said compound inhibits apoptosis resulting in stimulation of bone formation.

7. The method of claim 6, wherein said contacting of said osteoblast cells is selected from the group consisting of *in vitro*
15 osteoblast cells and an *in vivo* murine animal model.

8. The method of claim 7, wherein said *in vivo* murine animal model is selected from the group consisting of a SAMP6 mouse, a SAMR1 mouse and other strains of mice.

20

9. The method of claim 6, wherein said stimulation of bone formation is confirmed by methods selected from the group consisting of measuring BMD, measuring cancellous bone area, measuring cancellous bone formation rate, measuring the number of
25 osteoblasts per cancellous bone perimeter and measuring the number of osteocytes per bone area in said murine animal model following said

contact with said compound compared with a murine animal model in the absence of said contact with said compound.

10. The method of claim 6, wherein said determination of
5 apoptotic cells is selected from the group consisting of microscopy of stained cells, TUNEL, Hoescht 33258 dye and video image analysis.

11. A method of screening for a compound that reduces bone loss, comprising the steps of:

10 (a) treating osteoblast cells with a glucocorticoid;
(b) contacting said osteoblast cells with a test compound;
(c) determining the number of said osteoblast cells undergoing apoptosis; and

(d) comparing the number of apoptotic cells with
15 osteoblast cells that have been treated with said glucocorticoid but were not contacted with said test compound, wherein fewer apoptotic cells following contact with said test compound than in the absence of said contact with said test compound indicates that said compound inhibits apoptosis of osteoblast cells thereby reducing bone loss.

20

12. The method of claim 11, wherein said contacting of said osteoblast cells is selected from the group consisting of *in vitro* osteoblast cells and an *in vivo* murine animal model.

13. The method of claim 12, wherein said *in vivo* murine animal model is selected from the group consisting of a SAMP6 mouse and a SAMR1 mouse.

5 14. The method of claim 11, wherein said determination of apoptotic cells is selected from the group consisting of microscopy of stained cells, TUNEL, Hoescht 33258 dye and video image analysis.




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5

PTH

vehicle






FIG. 6



* p < 0.05 by ANOVA

FIG. 7



* p<0.05 by ANOVA

FIG. 8





FIG. 9



DBA: dibutyryl cAMP

* p < 0.05 by ANOVA

FIG. 10




FIG. 11A




FIG. 11B




FIG. 12




FIG. 13A




FIG. 13B




FIG. 13C

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/23393

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) : A01N 37/18; A61K 49/00; C12N 5/00, 5/02 US CL : 514/2; 424/9.1; 43/325 According to International Patent Classification (IPC) or to both national classification and IPC																				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 514/2; 424/9.1; 43/325 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) WEST, STN, BIOSIS, CAPLUS, MEDLINE																				
C. DOCUMENTS CONSIDERED TO BE RELEVANT																				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																		
X	HILL et al. Multiple Extracellular Signals Promote Osteoblast Survival and Apoptosis. Endocrinology. September 1997, Vol.138, No.9, pages 3849-3858.	6,9,10																		
A	MENG et al. Temporal Expression of the Anabolic Action of PTH in Cancellous Bone of Ovariectomized Rats. Journal of Bone and Mineral Research. 1996, Vol.11, No.4, pages 421-429.	1-5,7,8,11-14																		
A	CORNISH et al. An in vivo Model for the Rapid Assessment of the Local Effects of Parathyroid Hormone on Bone Histomorphometry. Bone. October, 1995, Vol.17, No.4, supplement, pages 249s-254s.	1-5,7,8,11-14																		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																				
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>"T"</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"X"</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"E" earlier document published on or after the international filing date</td> <td>"Y"</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"&"</td> <td>document member of the same patent family</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td></td> <td></td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family	"O" document referring to an oral disclosure, use, exhibition or other means			"P" document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																		
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																		
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																		
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family																		
"O" document referring to an oral disclosure, use, exhibition or other means																				
"P" document published prior to the international filing date but later than the priority date claimed																				
Date of the actual completion of the international search 22 DECEMBER 1999		Date of mailing of the international search report 11 FEB 2000																		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer KRIS PELI... MAYO Telephone No. (703) 308-0196																		

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/23393

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GUNNESS et al. Anabolic Effect of Parathyroid Hormone on Cancellous and Cortical Bone Histology. Bone. 1993, Vol.14, No.3, pages 277-281.	1-5,7,8,11-14
A	OKAMOTO et al. Femoral Peak Bone Mass and Osteoclast Number in an Animal Model of Age-Related Spontaneous Osteopenia. Anatomical Record. May 1995, Vol.242, No.1, pages 21-28.	1-5,7,8,11-14
A	LECKA-CZERNIK et al. Cellular and Molecular Biomarkers Indicate Precocious in vitro Senescence in Fibroblasts from SAMP6 Mice. Journal of Gerontology. 1997, Vol.52A, No.6, pages B331-B336.	1-5,7,8,11-14
A	JILKA et al. Linkage of Decreased Bone Mass with Impaired Osteoblastogenesis in a Murine Model of Accelerated Senescence. Journal of Clinical Investigation. April 1996, Vol.97, no.7, pages 1732-1740.	1-5,7,8,11-14
A	FUJIBAYASHI et al. Differential Aging Pattern of Cerebral Accumulation of Radiolabeled Glucose and Amino Acid in the Senescence Accelerated Mouse (SAM), a New Model for the Study of Memory Impairment. Biological and Pharmaceutical Bulletin. January 1994, Vol.17, No.1, pages 102-105.	1-5,7,8,11-14

Guti rr z, Chris

From: Gaul, Timothy
Sent: Friday, August 10, 2001 9:43 AM
To: Gutierrez, Chris
Subject: FW: PTH UPDATE (EO_010223)

Chris,

I think we need a copy of no. 2 below--

Tim
x 7-2688

-----Original Message-----

From: 3933C@stnk.FIZ-Karlsruhe.DE [mailto:3933C@stnk.FIZ-Karlsruhe.DE]
Sent: Friday, August 10, 2001 2:19 AM
To: TGAUL@amgen.com
Subject: PTH UPDATE (EO_010223)

AKM0853K 10 AUG 2001 11:21:06

SDI REQUEST 'PTHPEP/S'
MEMBER OF MFILE SDI REQ 'PTH/S'
PTH UPDATE (EO_010223)
RUN # 033 - AUG 09, 2001

2 ANSWERS PRINTED IN FORMAT 'IBIB AB MCLM'
IN FILE 'PATOSEP'

L11 ANSWER 1 OF 2 PATOSEP COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1999:403248 PATOSEP ED ***20010809*** EW
200131 FS OS
TITLE: GLUCOSE-DEPENDENT INSULINOTROPIC PEPTIDE FOR USE
AS AN OSTEOTROPIC HORMONE.
GLUKOSE-ABHAENGIGES, INSULINOTROPISCHES PEPTID
FUEr DIE VERWENDUNG ALS OSTEOTROPES HORMON.
PEPTIDE GLUCODEPENDANT INSULINOTROPE UTILISE
COMME HORMONE OSTEOTROPE.
INVENTOR(S): ISALES, Carlos, M., 3413 Woodstone Place,
Augusta, GA 30909, US;
BOLLAG, Roni, J., 231 Watervale Road, Martinez,
GA 30907, US;
RASMUSSEN, Howard, 820 Bassett Lane, Augusta, GA
30909, US
PATENT ASSIGNEE(S): Medical College Of Georgia Research Institute,
Inc., 1120 15th Street, Augusta, GA 30912-4810,
US
PATENT ASSIGNEE NO: 2679130
AGENT: Farwell, William Robert et al., PHILLIPS & LEIGH
5 Pemberton Row, London EC4A 3BA, GB
AGENT NUMBER: 30541
SOURCE: Wila-EPZ-2001-H31-T1a
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in
Englisch
DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R
FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R
NL; R PT; R SE; R AL; R LT; R LV; R MK; R RO; R

SI
PATENT INFO.PUB.TYPE: EPA1 EUROPÄISCHE PATENTANMELDUNG (Internationale
Anmeldung)

PATENT INFORMATION:

	PATENT NO	KIND DATE
	EP 1119625	A1 20010801
'OFFENLEGUNGS' DATE:		20010801
APPLICATION INFO.:	EP 1999-950250	19991007
PRIORITY APPLN. INFO.:	US 1998-103333	19981007
	US 1998-103495	19981008
RELATED DOC. INFO.:	WO 99-US23365	991007 INTAKZ
	WO 0020592	000413 INTPNR

EPA1 EUROPÄISCHE PATENTANMELDUNG (Internationale Anmeldung)
EPLU LEGAL STATUS, UPDATE

ABEN WO-ABSTRACT:

The examples demonstrate that GIP receptor mRNA and protein are present in normal bone and osteoblastic-like cell lines, and that high-affinity receptors for GIP can be demonstrated by (EXP=125) I GIP binding studies. When applied to osteoblast-like cells (SaOS2), GIP stimulated an increase in cellular cAMP content and in intracellular calcium, with both responses being dose dependent. Moreover, administration of GIP results in elevated expression of collagen type I mRNA as well as an increase in alkaline phosphatase activity. Both of these effects reflect anabolic actions of presumptive osteoblasts. These results provide the first evidence that GIP receptors are present in bone and osteoblastic-like cells and that GIP modulates the function of these cells. GIP has anabolic actions on remodeling bone, increasing vertebral bone density in a rat model of osteoporosis. GIP at 10nM ***inhibits*** ****PTH*** -induced bone resorption in a fetal long bone assay and stimulates the synthesis of type I collagen mRNA. Transgenic mice overexpressing GIP have increased bone density compared to same age controls. GIP or analogs thereof can therefore be used as a therapeutic to inhibit bone resorption and to maintain or increase bone density. GIP antagonists, compounds which block binding to the GIP receptor, can be used to decrease bone density.

L11 ANSWER 2 OF 2 PATOSEP COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1999:396890 PATOSEP ED ***20010809*** EW
200131 FS OS

TITLE: METHODS OF SCREENING FOR APOPTOSIS-CONTROLLING
AGENTS FOR BONE ANABOLIC THERAPIES AND USES
THEREOF.
VERFAHREN FÜR DAS SCREENING AUF WIRKSTOFFE FÜR
DIE ANABOLE KNOCHENTHERAPIE, DIE DIE APOPTOSIS
KONTROLLIEREN, UND IHRE VERWENDUNG.
PROCEDES DE DETECTION D'AGENTS REGULANT
L'APOPTOSE DESTINES A LA THERAPIE ANABOLISANTE
OSSEUSE ET UTILISATIONS DE TELS AGENTS.
INVENTOR(S): MANOLAGAS, Stavros, C., 35 River Ridge Circle,
Little Rock, AR 72227, US;
JILKA, Robert, L., 14202 Clarborne, Little Rock,
AR 72211, US;
WEINSTEIN, Robert, S., 11 Chalmette, Little Rock,
AR 72211, US;
BELLIDO, Teresita, 9 Westglen Cove, Little Rock,
AR 72211, US
PATENT ASSIGNEE(S): THE BOARD OF TRUSTEES OF THE UNIVERSITY OF
ARKANSAS, 2404 N. University Avenue, Little Rock,
AR 72207-3608, US
PATENT ASSIGNEE NO: 1138583
AGENT: Hallybone, Huw George et al., CARPMAELS AND

RANSFORD 43 Bloomsbury Square, London WC1A 2RA,
GB

AGENT NUMBER:

53031

SOURCE:

Wila-EPZ-2001-H31-T3a

DOCUMENT TYPE:

Patent

LANGUAGE:

Anmeldung in Englisch; Veroeffentlichung in
Englisch

DESIGNATED STATES:

R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R
FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R
NL; R PT; R SE; R AL; R LT; R LV; R MK; R RO; R
SI

PATENT INFO.PUB.TYPE:

EP A1 EUROP AEISCHE PATENTANMELDUNG (Internationale
Anmeldung)

PATENT INFORMATION:

PATENT NO KIND DATE

EP 1119251 A1 20010801

'OFFENLEGUNGS' DATE:

20010801

APPLICATION INFO.:

EP 1999-953094

19991007

PRIORITY APPLN. INFO.:

US 1998-103385

19981007

US 1999-116409

19990119

RELATED DOC. INFO.:

WO 99-US23393

991007 INTAKZ

WO 0019823

000413 INTPNR

EP A1 EUROP AEISCHE PATENTANMELDUNG (Internationale Anmeldung)

EPLU LEGAL STATUS, UPDATE

ABEN

WO-ABSTRACT:

The present invention demonstrates that human ***parathyroid***
hormone ***1*** -34 (***hPTH*** (***1*** -34))
exerts anti-apoptotic effects on osteoblasts when administered in
an intermittent fashion to mice in vivo. The present invention
further demonstrates that bovine ***PTH*** (***1*** -34)
(bPTH(1-34)) prevents glucocorticoid-induced apoptosis of
osteoblastic and osteocytic cells in vitro. Therefore, the
present invention demonstrates that the previously established
anabolic effects of PTH on the skeleton are mediated by its
ability to postpone osteoblast apoptosis, as opposed to a
stimulatory effect on osteoblastogenesis. The present invention
provides methods of screening agents for anti-apoptotic effects
on osteoblasts, wherein such agents stimulate and/or restore bone
in osteopenic individuals, or prevent bone loss caused by agents
such as glucocorticoids.

THIS PAGE BLANK (USPTO)